Aker Solutions logo
HomeIndustries And ServicesSuppliersCorporate responsibilityMediaInvestor RelationsCareerAbout us
Aker Solutions: global engineering & construction services, technology products and integrated solutions
  
 

Market Entry Facility RX83


Client: GlaxoSmithKline
Location: Wavre, Belgium
Completion: 2001
Scope of Work: Concept, Basic and Extended Basic Engineering
Project Value: £29.0 million
 


Market Entry Facility RX83


Features

  • Bulk bacterial vaccines production facility  
  • Two production suites with centralised services  
  • Biosafety containment level BL3 for live areas
  • Flexible processing areas allowing rapid equipment changeover
  • Campaign production for different products
  • GMP compliance with EU and US FDA requirements
  • Clean room classifications to EU grades B, C and D
  • Integrated with off-plot Energy Centre for building utilities supply 
  • Utilities floor incorporating kill tanks, clean utilities and building services 
  • Future expansion building bay incorporated for scaled up process 
  • Mezzanine level for HVAC systems above production level  
  • Plant wide SCADA and materials tracking systems

© Aker Solutions|Sitemap|Terms of Use| Printable version